Price History
Feb 9, 2026 — Apr 4, 2026Investment Snapshot
- Trading 1% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 6/9 — moderate financial health
- ROE of 10.8% — below-average profitability
PRESTIGE CONSUMER HEALTHCARE INC. (PBH) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NYSE , with a market capitalisation of $2.9 billion . Key value metrics: P/E ratio 14.6, P/B ratio 1.58, Piotroski F-Score 6 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
PRESTIGE CONSUMER HEALTHCARE INC. — Fundamental Analysis Summary
PRESTIGE CONSUMER HEALTHCARE INC. (PBH) is currently trading 1% above its Graham Number of $60.24, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries a reasonable trailing P/E ratio of 14.6x.
On financial health, PBH shows a moderate Piotroski F-Score of 6/9, and modest return on equity of 10.8% (sector average: -19.8%), and manageable leverage with a debt-to-equity ratio of 0.56.
StockPik's composite Value Score for PBH is 74/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
PBH reports a solid gross margin of 55.6% (sector average: 33.5%) and a strong operating margin of 29.7%.
PBH shows revenue growing at 1% year-over-year, with earnings growing at 3%.